Association of glucagon-like peptide 1 receptor agonists with cancer risk in obesity adults with and without diabetes: A target trial emulation study.

医学 糖尿病 肥胖 胰高血糖素样肽-1 内科学 2型糖尿病 胰高血糖素样肽1受体 癌症 内分泌学 仿真 肿瘤科 临床试验 兴奋剂 受体 经济增长 经济
作者
Hao Dai,Yao An Lee,Ying Lü,Thomas J. George,Jingchuan Guo,Jiang Bian
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 10508-10508
标识
DOI:10.1200/jco.2025.43.16_suppl.10508
摘要

10508 Background: The use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has substantially expended given their remarkable benefits in managing obesity. Yet, their impact on long-term cancer risk remains unclear, with existing real-world evidence being limited and yielding conflicting results. Methods: This retrospective cohort study followed a target trial emulation design using 2014–2024 OneFlorida+ electronic health records (EHR) data. Adults (≥18 years) eligible for anti-obesity medications (AOMs) and without a cancer history were included. We compared GLP-RA users vs. non-users, with 1:1 propensity score matching applied to balance baseline factors between the two groups. The primary outcomes include the incidence of 16 obesity-associated cancers (liver, thyroid, pancreatic, bladder, colorectal, lung, kidney, breast, endometrial, meningioma, esophageal adenocarcinoma, gallbladder, upper stomach, ovarian, multiple myeloma, and prostate), assessed over a follow-up period of up to 10 years. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), and cumulative incidences were estimated using Kaplan-Meier analyses. Results: After matching, 43,317 GLP-1RA users were compared with 43,315 non-users. The incidence rates of the 16 cancers were 20.5 versus 23.6 per 1,000 person-years, respectively, indicating a significantly lower overall cancer risk among GLP-1RA users (HR, 0.83 [95% CI, 0.76–0.91]) compared to non-users. In particular, GLP-1RA use was associated with a reduced risk of endometrial cancer (HR, 0.75 [95% CI, 0.57–0.99]), ovarian cancer (HR, 0.53 [95% CI, 0.29–0.96]), meningioma (HR, 0.69 [95% CI, 0.48–0.97]), and esophageal adenocarcinoma (HR, 0.34 [95% CI, 0.12–0.94]). However, GLP-1RA users showed a trend toward an increased risk of kidney cancer (HR, 1.38 [95% CI, 0.99–1.93]), particularly among the younger adults (≤65 years) and overweight patients (BMI 27–29.9). Conclusions: In this large cohort of real-world obesity population with and without diabetes, GLP-1RA use was associated with an overall reduction in obesity-related cancer risk, as well as lower risks of several specific cancers. However, a potential elevated risk of kidney cancer, especially in younger or moderately obese individuals, highlights the need for targeted surveillance and longer-term follow-up to clarify the underlying mechanisms and clinical implications of these findings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LYQ完成签到,获得积分10
刚刚
1秒前
Jasper的应助被胡萝卜卜采纳,获得10
1秒前
3秒前
syx完成签到,获得积分20
4秒前
syvshc的应助被crazycathaha采纳,获得10
4秒前
凡夫俗女的应助被crazycathaha采纳,获得10
5秒前
syvshc的应助被crazycathaha采纳,获得10
5秒前
zero完成签到,获得积分10
5秒前
张伟发布了新的文献求助10
6秒前
7秒前
桃不掉了完成签到 ,获得积分10
8秒前
桐桐的应助被科研通管家采纳,获得10
8秒前
汉堡包的应助被科研通管家采纳,获得10
8秒前
8秒前
超级无敌的应助被科研通管家采纳,获得10
8秒前
syx发布了新的文献求助10
8秒前
Akim的应助被科研通管家采纳,获得10
8秒前
丘比特的应助被科研通管家采纳,获得10
9秒前
9秒前
9秒前
星辰大海的应助被科研通管家采纳,获得30
9秒前
9秒前
超级无敌的应助被科研通管家采纳,获得10
9秒前
烟花的应助被风1采纳,获得10
9秒前
9秒前
9秒前
超级无敌的应助被科研通管家采纳,获得10
9秒前
秋风的应助被科研通管家采纳,获得20
10秒前
Jeremy完成签到,获得积分10
10秒前
Ava的应助被科研通管家采纳,获得10
10秒前
10秒前
孙笑川爱学习完成签到,获得积分10
11秒前
充电宝的应助被fengfeng采纳,获得10
11秒前
11秒前
苻莞完成签到,获得积分10
12秒前
乐乐1314完成签到,获得积分10
12秒前
刘刘发布了新的文献求助10
14秒前
orixero的应助被骑着上帝去流浪采纳,获得10
16秒前
思源的应助被胡萝卜卜采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191366
求助须知:如何正确求助?哪些是违规求助? 9578238
关于积分的说明 21857620
捐赠科研通 7790721
什么是DOI,文献DOI怎么找? 3436607
关于科研通互助平台的介绍 2560359
邀请新用户注册赠送积分活动 2483340